Drug intelligence / Profile preview

vorinostat + lenalidomide + carfilzomib + dexamethasone

Development stage: Phase 2
Lead developer: Hackensack Meridian Health
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

A four-drug combination regimen consisting of vorinostat (a histone deacetylase inhibitor), lenalidomide (an immunomodulatory agent), carfilzomib (a second-generation proteasome inhibitor), and dexamethasone (a corticosteroid). This combination leverages the synergistic anti-multiple myeloma activity of these agents with different mechanisms of action. The regimen has been studied in phase I clinical trials for relapsed and/or refractory multiple myeloma.

Other names: QUAD regimenVorinostat combination therapy

Targets

PSMB5 (Proteasome subunit beta Type-5)CRBN (Cereblon)GR (Glucocorticoid receptor)HDAC (HDAC family)TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on vorinostat + lenalidomide + carfilzomib + dexamethasone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on vorinostat + lenalidomide + carfilzomib + dexamethasone.